20.500.12556/DiRROS-30474 Idarubicin-loaded drug-eluting microspheres transarterial chemoembolization for intermediate stage hepatocellular carcinoma safety, efficacy, and pharmacokinetics Transarterijska kemoembolizacija z idarubicinom pri bolnikih z jetrnoceličnim karcinomom v srednjem stadiju bolezni Background: Transarterial chemoembolization (TACE) is the treatment of choice for the intermediate stage hepatocellular carcinoma (HCC). Doxorubicin remains the most used chemotherapeutic agent in TACE, although in vitro screening has demonstrated that idarubicin exhibits greater cytotoxicity against HCC. This study aimed to evaluate safety, efficacy, and pharmacokinetics of idarubicin-loaded drug-eluting microspheres TACE (DEMIDA-TACE) in intermediate stage HCC patients. Patients and methods: Between September 2019 and December 2021, 31 consecutive intermediate stage HCC patients (96.8% cirrhotic) were included to this study. 2 mL of LifePearl™ microspheres (100 μm) loaded with 10 mg of 1 mg/mL idarubicin were used for treatment. The adverse events, objective response rate (ORR), progression free survival (PFS), time to TACE untreatable progression (TTUP), median overall survival (mOS), and pharmacokinetics were evaluated. Results: There were 68 TACE procedures performed. Adverse events grade ≥ 3 were noted after 29.4% procedures. The ORR was 83.9%, median PFS and TTUP were 10.5 months (95% CI: 6.8-14.3 months) and 24.6 months (95% CI: 11.6-37.6 months), respectively. Median OS was 36.0 months (95% CI: 21.1-50.9 months). Significant differences between patients achieving objective response (OR) and those with progressive disease were observed regarding idarubicinol and combined idarubicin-idarubicinol plasma concentrations at 72 hours post-procedure, higher plasma concentrations were observed in patients achieving OR (p = 0.014 and 0.014; cut-off values 1.2 and 1.29 ng/mL, respectively). Conclusions: DEMIDA-TACE emerges as a safe and effective method of treatment for the intermediate stage HCC with low rates of adverse events alongside high tumor response, favourable disease control and overall survival. Idarubicinol and combined idarubicin-idarubicinol plasma concentrations at 72 hours post-procedure may serve as prognostic factors for achieving OR. drug-eluting microspheres transarterial chemoembolization efficacy hepatocellular carcinoma idarubicin pharmacokinetics safety transarterijska kemoembolizacija mikrosfer ki izločajo zdravilo učinkovitost hepatocelularni karcinom idarubicin farmakokinetika varnost true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik Neznano 2026-06-26 14:13:41 2026-06-26 14:13:42 2026-06-27 03:52:16 0000-00-00 00:00:00 2024 0 0 Soavtorji: Josko Osredkar, Alojz Smid, Klemen Steblovnik, Mark Popovic, Igor Locatelli, Jurij Trontelj, Peter Popovic; str. 517-526, VII no. 4 Vol. 58 Dec. 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2024-12-01 616-006 1318-2099 10.2478/raon-2024-0052 210906883 https://sciendo.com/article/10.2478/raon-2024-0052 1 7a49ace1-7158-11f1-b414-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=46280 RAZ_Korsic_Spela_2024.pdf RAZ_Korsic_Spela_2024.pdf 1 E42B65FFBEE84FCE33417A905F59C59A edbc9ebc0d12c9f12f62ef464014b11a69070602834dd7a21e76803296a59134 919fb4fd-7158-11f1-b414-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=46281 Društvo radiologije in onkologije 0 0 0